Immunome (IMNM) vs Maravai LifeSciences (MRVI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Maravai LifeSciences (MRVI) has outperformed Immunome (IMNM) over the past year, gaining 86.1% versus a loss of 15.3%. Over five years, IMNM leads with a -7.5% price change compared with -83.2% for MRVI. Immunome is the larger company by market cap ($1.85 billion vs $1.81 billion), about 1.0 times the size.
Maravai LifeSciences converts more of its revenue into profit, with a net margin of -70.4% versus -3060.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMNM | MRVI |
|---|---|---|
| Share price | $15.69 | $6.98 |
| Market cap | $1.85B | $1.81B |
| 1-day change | -5.54% | -2.92% |
| YTD return | -26.96% | +114.77% |
| 1-year return | -15.33% | +86.13% |
| 5-year return | -7.54% | -83.18% |
| EPS (TTM) | $-2.63 | $-0.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $6.94M | $185.74M |
| Revenue growth (YoY) | -23.23% | -28.34% |
| Net income (latest FY) | $-212.39M | $-130.77M |
| Gross margin | — | 18.30% |
| Operating margin | -3228.83% | -115.89% |
| Net margin | -3059.99% | -70.41% |
| 52-week high | $30.06 | $9.42 |
| 52-week low | $15.55 | $2.80 |
| Distance from 52-week high | -47.80% | -25.90% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +123.90% | +38.11% |
| Average volume | 1.36M | 2.72M |
| Shares outstanding | 118.07M | 149.25M |
| Employees | 267 | 410 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MRVI has outperformed IMNM by 101.5 percentage points over the past year.
- Maravai LifeSciences is more profitable, keeping -70.4 cents of every revenue dollar as net income versus -3060.0 cents for Immunome.
- Immunome grew revenue faster in its latest fiscal year (-23.23% vs -28.34%).
About Immunome
IMNM stock →Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 267 employees
About Maravai LifeSciences
MRVI stock →Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS.
Health Care · Biotechnology: Pharmaceutical Preparations · 410 employees
IMNM vs MRVI FAQ
Which is bigger, Immunome or Maravai LifeSciences?
Immunome (IMNM) is larger, with a market capitalization of $1.85B compared with $1.81B for Maravai LifeSciences (MRVI).
Which stock has performed better over the past year, IMNM or MRVI?
MRVI returned +86.13% over the past 12 months, compared with -15.33% for IMNM (price return, excluding dividends). Past performance does not predict future results.
Are Immunome and Maravai LifeSciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.